Global /China /Healthcare /Medical Devices /300685
chevron_leftBack
Amoy Diagnostics Co., Ltd. logo

Amoy Diagnostics Co., Ltd.

300685
SHE: 300685 Delayed
20.21CNY -1.5%
2.99 USD
As of 14 June 2026, Amoy Diagnostics Co., Ltd. has a market cap of $1.18B USD, ranking #9754 globally and #2663 in China. It ranks #850 in the Healthcare sector, and #174 in the Medical Devices industry.
Global Rank
9754
Country Rank
2663
Sector Rank
850
Industry Rank
174
Key Stats
Market Cap
$1.18BUSD
8.02B CNY
Enterprise Value
$1.0BUSD
6.79B CNY
Revenue (TTM)
$176.76MUSD
1.2B CNY
EBITDA (TTM)
$63.52MUSD
429.88M CNY
Net Income (TTM)
$53.31MUSD
361.26M CNY
EBITDA Margin
36%
Profit Margin
30%
PE Ratio
22.8
Forward PE
21.4
PS Ratio
6.7
PB Ratio
3.9
EV/EBITDA
15.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Jiemin Luo open_in_new
Employees
1,144
Founded
2008
Website
amoydx.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-1.5% -9% -9.6% -7.6% -12% -2.8%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
300685
厦门艾德生物医药科技股份有限公司 Class A
ISIN: CNE1000034D3
Shares Out.:
388.268M1 Shares Float: 250.31M2
TV:
SA:
YF:
GF:
BA:
MS:
20.21 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Amoy Diagnostics Co., Ltd.

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a comprehensive genomic profiling assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel, detects multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel, detects EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. It also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel solutions; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel solutions. In addition, the company offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was founded in 2008 and is based in Xiamen, China.

Similar Companies

Industry: Medical Devices (China)
Name
Market Cap diff.
PE
$30.06B
203.66B CNY
2K%
26.0
$13.61B
92.23B CNY
1K%
48.5
$5.61B
38.02B CNY
374%
23.4
$5.52B
37.43B CNY
367%
52.7
688617
$5.04B
34.14B CNY
326%
39.6
$4.55B
30.86B CNY
285%
13.7
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
$173.27B
15K%
25.8
$160.73B
13K%
56.7
$159.07B
13K%
25.6
DHR
$126.55B
11K%
34.7
SYK
$120.69B
10K%
38.3
MDT
$101.9B
9K%
22.2
chevron_leftBack